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Abstract  
 
There has been renewed interest in the use of sporozoite-based approaches for malaria 
vaccination and controlled human infections, and several sets of human challenge studies 
have recently completed. A study undertaken in Tanzania and published in 2014 found 
dose-dependence between 10,000 and 25,000 sporozoite doses, as well as divergent times-
to-parasitemia relative to earlier studies in European volunteers. However, this analysis 
shows that these conclusions are based upon suboptimal analytical methods; with more 
optimal analysis, there is no evidence for dose-dependence within this dose range; and 
more importantly, no evidence for differences in event times between Dutch and 
Tanzanian study sites. While these finding do not impact the reported safety and 
tolerability of PfSPZ, they highlight critical issues that should be comprehensively 
considered in future challenge studies. 
 
 
Experimental injection of infective malaria parasites as sporozoites is currently undergoing a re-
evaluation as a viable vaccine strategy for prevention of malaria infections in humans, and for 
controlled human malaria infection (CHMI). A recently published paper reports on the use of 
cryopreserved Plasmodium falciparum sporozoites (‘PfSPZ Challenge,’ Sanaria Inc.) for 
challenge experiments in human volunteers in Tanzania.1 
 
I applaud the authors’ efforts to bring these critically important studies to malaria-endemic 
settings in sub-Saharan Africa, and agree that this is truly a milestone in global efforts towards 
development of a sporozoite vaccine against malaria and controlled human infections. However, 
in light of the enormous financial, technical and ethical challenges underlying these bridging 
studies I believe it is critical that they provide accurate guidance for future trials.  
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There are several aspects of the published analysis that have major impacts on Shekalaghe et 
al’s conclusions. With more appropriate analysis, and contrary to the reported results, their 
data do not provide any evidence for dose-response in sporozoite dosing, and more importantly 
there is no evidence for statistically significant differences in reported times-to-parasitemia 
between Tanzanian and Dutch cohorts. 
 
First and foremost, the prepatent periods (time from sporozoite exposure to febrile illness) in 
this study have been compared as geometric means via a non-parametric Wilcoxon rank-sum 
test. While this is common practice in some fields, there are more appropriate methods for the 
analysis of time-to-event data,2 and a large body of literature exists with approaches that allow 
comprehensive analyses of these types of data.3 In earlier work with Plasmodium vivax, it was 
shown that application of this, and other suboptimal methods may lead to erroneous conclusions 
regarding dose-dependence in sporozoite inoculations.4 
 
A second major issue, which has received extensive attention in the epidemiological and clinical 
trials literature but was not considered by the authors, is one of potential biases from exclusion 
in the analysis of any patients originally randomized.5 This problem is especially acute in these 
studies due to the limited sample size. In the published earlier work three patients were 
removed from the analysis- however these data need to be included in an ‘intent-to-treat’ 
analysis to avoid potentially biased conclusions. The ‘failed’ infections that were treated but 
removed from the analysis may well have been delayed incubation periods- while this 
phenomenon is better documented in P. vivax infections, it has also been reported in P. 
falciparum infections.6,7 While extended follow-up is not feasible or ethical in these challenge 
studies, a censoring date should be explicit in the research protocol. 
 
To quantify the impact of these issues, I have re-analyzed these study data using statistical 
analyses optimized for these types of data (see Figure 1 and Table 1). This re-analysis consisted 
of 1) unadjusted comparisons using logrank-type tests (using alternatives where the survival 
curves are crossing) followed by 2) multivariate models. 
 
While the authors’ report that “Volunteers in the 10,000 PfSPZ group had a significantly 
different pre-patent period than in the 25,000 PfSPZ group (geometric mean [GM] of 15.4 and 
13.5 days, Wilcoxon, P = 0.023)”1 I find no evidence of differences using a logrank test (p= 
0.179), and no differences in qPCR times (Renyi logrank p = 0.266). Kaplan-Meier plots of 
these results are show in Figure 1, Panels A and B. Moreover, the potential impact of not fully 
considering patient censoring is readily apparent in the differences between the full and reduced 
datasets (Table 1). 
 
Additionally, the authors when comparing results to their earlier studies8 were surprised to find 
that “…the GM pre-patent period for the Tanzanians who received the 10,000 PfSPZ dosage 
regimen was 15.4 days, and the GM pre-patent period for the Dutch was 12.6 days (P = 0.0192, 
   Page 3 
Wilcoxon 2-tailed).” Unadjusted comparisons of these times (N=18) taking into account time-to-
event data provides no evidence of differences (logrank p= 0.288; Renyi logrank = 0.110). 
 
Finally, to comprehensively assess the overall impacts of dose and study site on event times, 
multivariate Cox and Poisson were used to provide full covariate adjustment, and show no 
evidence for statistically significant differences in event times between any of the dose categories 
or between the two study sites (Figure 1, panel C;  results by microscopy, Table 2; results by 
PCR, Table 3) in a direct comparison amongst the combined cohorts (N=42). 
 
Importantly, while the results from this re-analysis do not impact the reported safety or 
tolerability of PfSPZ challenge, they highlight critically important areas that require further 
detailed consideration. First, these results suggest that there is no evidence for dose response 
within this range of sporozoite inoculations, which consequent potential to complicate dose 
ranging in future studies. Secondly, these results should allay the authors’ concerns regarding 
any potential differences in response to challenge between Dutch and Tanzania volunteers in 
future work, and, obviate the need for the hypotheses suggested in their discussion (e.g. genetic 
differences in merozoites release).  
 
In summary, greater consideration and wider utilization of comprehensive survival analyses to 
provide sound conclusions towards informing further work using these challenging and critically 
important experiments. 
 
Note: Appendix 1 contains detailed statistical methods; Appendix 2 contains the dataset for this 
analysis. 
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Figure 
 
Figure 1.  Kaplan-Meier curves comparing times-to-parasitemia by sporozoite dose groups in 
human sporozoite challenge studies. Panel A. Tanzanian cohort via microscopy; Panel B. 
Tanzanian cohort via PCR; Panel C. Combined Tanzanian and Dutch cohorts via PCR. 
 
 
 
 
Tables  
 
 
Table 1.  Non-parametric comparisons between time-to-parasitemia in the 10,000 vs. 25,000 
sporozoite dose groups; full data and truncated data (Tanzanian study).   
 
 
Study Endpoint Comparison Test Full data 
(N=24) 
p-value 
Reduced data 
(N=21) 
p-value 
Parasitemia 
(microscopy) 
10,000 vs. 25,000 
dose 
logrank 0.179 0.050 
Parasitemia 
(PCR) 
10,000 vs. 25,000 
dose 
Renyi-  
logrank 
0.266 0.102 
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Table 2.  Multivariate Cox model for time-to-parasitemia by microscopy in human sporozoite 
challenge trials, comparing dose and combined study cohorts (N= 42). Note: HR= Hazard ratio. 
 
 
Outcome Risk factor HR  HR 95% CI p-value 
Parasitemia via microscopy 2,500 sporozoite dose 1.17 0.31 – 4.45 0.821 
 10,000 sporozoite dose ref. - - 
 25,000 sporozoite dose 1.34 0.67 – 2.71 0.408 
Study cohort Tanzania ref - - 
 Netherlands 1.21 0.52 – 2.81 0.655 
 
 
Table 3.  Multivariate Poisson model for time-to-parasitemia by PCR in human sporozoite 
challenge trials, comparing dose and combined study cohorts (N= 42). Notes: Poisson model 
utilized due to evidence of non-proportional hazards in Cox models; IRR= Incidence rate ratio. 
 
 
Outcome Risk factor IRR  IRR 95% CI p-value 
Parasitemia via PCR 2,500 sporozoite dose 0.98 0.32 – 3.03 0.973 
 10,000 sporozoite dose ref. - - 
 25,000 sporozoite dose 1.02 0.51 – 2.07 0.950 
Study cohort Tanzania ref - - 
 Netherlands 1.00 0.47 – 2.12 0.997 
 
 
Appendix 1- Detailed Methods 
 
The endpoints for the survival analyses were taken from table 2 in reference1 and table 2 in 
reference.8 In the Tanzanian studies, two of the excluded patients were censored at the reported 
times (volunteer 40055-20 at 19 days, and volunteer 50057-20 at 11 days); insufficient data was 
reported to censor the third volunteer (40010-20) who was also censored on day 19. Patients in 
the Dutch studies were censored on day 21 when presumptive treatment was given. Dosage was 
modeled as an ordinal variable; inclusion as a numeric had no impact on model fit. 
 
Model parsimony was assessed using Akaike and Bayesian information criteria; and all Cox 
models were assessed for proportional hazard violations using scaled Schoenfeld residuals plus 
graphical comparisons with Kaplan-Meier curves.  
 
In situations where Kaplan-Meier curves cross, conventional logrank-type tests are invalid; 
therefore Renyi-family tests (developed for this specific situation) were used to compare 
unadjusted survival between groups.9,10  
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In multivariate Cox models for PCR-endpoints in the combined cohort, proportional hazard 
assumptions were not met, so Poisson models are presented; other modeling strategies (stratified 
Cox, flexible parametric, and parametric models) produced comparable estimates and consistent 
conclusions. Standardized residuals were used to assess fit of multivariate models. 
 
The Renyi tests were implemented using the –survmisc- package;10 analyses were performed in 
Stata 13.1 (College Station, Texas, USA), and R software (version 3.0.1).11  
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Appendix 2- Dataset for analysis 
 
index study_id PP_slide dose PP_pcr failure study 
1 10002-20 18.6 10000 16 1 Tanzanian 
2 10023-20 18.7 10000 15 1 Tanzanian 
3 30035-20 18.7 10000 14 1 Tanzanian 
4 40010-20 19 10000 19 0 Tanzanian 
5 50041-20 14.6 10000 13 1 Tanzanian 
6 60008-20 12.8 10000 10.5 1 Tanzanian 
7 60026-20 12.7 10000 11.5 1 Tanzanian 
8 70001-20 14.2 10000 11 1 Tanzanian 
9 70014-20 15.8 10000 12.5 1 Tanzanian 
10 70031-20 14.2 10000 11 1 Tanzanian 
11 70044-20 17.6 10000 15 1 Tanzanian 
12 90047-20 13.7 10000 11 1 Tanzanian 
13 20056-20 18.7 25000 16 1 Tanzanian 
14 20064-20 11.1 25000 9 1 Tanzanian 
15 20070-20 12.6 25000 9.5 1 Tanzanian 
16 30053-20 13.7 25000 12 1 Tanzanian 
17 30060-20 13.5 25000 11 1 Tanzanian 
18 40055-20 19 25000 19 0 Tanzanian 
19 40068-20 13.4 25000 11 1 Tanzanian 
20 50050-20 12.7 25000 10 1 Tanzanian 
21 50057-20 11 25000 11 0 Tanzanian 
22 60051-20 12.7 25000 11 1 Tanzanian 
23 60072-20 14 25000 11.5 1 Tanzanian 
24 80058-20 13.7 25000 11 1 Tanzanian 
25 696 -18 12.3 2500 9.6 1 Dutch 
26 711-08 14 2500 12 1 Dutch 
27 795-06 21 2500 21 0 Dutch 
28 935-01 14 2500 10.6 1 Dutch 
29 937-20 12.3 2500 10.6 1 Dutch 
30 940 -14 12.3 2500 10.3 1 Dutch 
31 119-03 12.6 10000 9.6 1 Dutch 
32 603-11 13 10000 11 1 Dutch 
33 736-04 11 10000 9.6 1 Dutch 
34 783-25 13.3 10000 10.6 1 Dutch 
35 788-21 14 10000 11 1 Dutch 
36 925-26 21 10000 21 0 Dutch 
37 647-30 14 25000 9.3 1 Dutch 
38 720-13 12.3 25000 10.3 1 Dutch 
39 789-15 21 25000 21 0 Dutch 
40 806-09 12.3 25000 9 1 Dutch 
41 909-29 14.3 25000 11.3 1 Dutch 
42 926-24 12.3 25000 10 1 Dutch 
 
Codebook  
index: ID for analysis 
study_id: patient ID in original publications 
PP_slide: reported prepatent period via microscopy (days) 
dose: reported sporozoite dosage 
PP_pcr: reported prepatent period via PCR (days) 
failure: 1= parasitemic; 0 = censored 
study: study cohort 
